AMCP Submits Comments on MCIT Rule

Topic(s):

Legislation & Regulation , Medicare , Medicaid

The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare & Medicaid Services (CMS) for the opportunity to provide comments in response to its interim final rule with comment (IFC) period titled “Medicare Program; Medicare Coverage of Innovative Technology (MCIT) and Definition of “Reasonable and Necessary”; Delay of Effective Date; Public Comment Period (CMS-3372-IFC)” published on March 17, 2021. We appreciate the opportunity to leverage our members’ expertise in offering feedback on this rule.

View More

Related

Capitol Hill, U.S. Capitol, IRA Workshop
Letters, Statements & Analysis

AMCP Comments on the 2025 Medicare Physician Fee Schedule

On September 9, AMCP submitted comments praising CMS’s proposal to cover Digital Mental Health Treatment devices (DMHTs) under Medicare Part B. AMCP urges CMS to use its authority to cover all FDA-cleared, prescription only digital health products and develop appropriate coding and payment methodologies to promote adoption of these innovative technologies.
Medicare

News & Resources by Topic

Visit the AMCP Calendar

AMCP offers a wide variety of educational opportunities, from events and webinars to online training.

News & Resources for:

Register Today
AMCP Nexus 2024 Logo Green

 

October 14-17 • • • MGM Grand, Las Vegas